Patents Assigned to FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ
-
Patent number: 11858972Abstract: The present invention relates to new peptidic compounds, more specifically to micropeptides derived from lncRNAs implicated in cancer and cellular plasticity. It also relates to the use of the said micropeptides in the treatment of proliferative diseases, more specifically in the treatment of cancer.Type: GrantFiled: March 15, 2019Date of Patent: January 2, 2024Assignee: Fundació Privada Institut d'Investigació Oncològica de Vall HebronInventors: Maria Abad Méndez, Olga Boix Sánchez, Emanuela Greco, Iñaki Merino Valverde
-
Patent number: 11851709Abstract: The present invention refers to an in vitro method for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.Type: GrantFiled: December 7, 2016Date of Patent: December 26, 2023Assignees: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL D'HEBRON, FUNDACIÓN SOLTI, FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA, HOSPITAL CLÍNIC DE BARCELONAInventors: Aleix Prat Aparicio, Javier Cortés Castán, Antonio Llombart Cussac
-
Patent number: 11427621Abstract: The invention relates to a polypeptide comprising or consisting of the polypeptide of SEQ ID NO: 1 wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine, or a functionally equivalent variant of said polypeptide wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine and their use in medicine, particularly in the prevention and/or treatment of cancer.Type: GrantFiled: July 17, 2017Date of Patent: August 30, 2022Assignees: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL HEBRONInventors: Laura Soucek, Toni Jauset González, Marie-Eve Beaulieu
-
Patent number: 11390670Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.Type: GrantFiled: December 18, 2017Date of Patent: July 19, 2022Assignees: MEDIMMUNE LIMITED, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGIC, FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA IInventors: Joan Seoane Suarez, Judit Anido Folgueira, Johan Fransson, Jean-Philippe Julien, Swetha Raman
-
Patent number: 11339205Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.Type: GrantFiled: June 6, 2019Date of Patent: May 24, 2022Assignees: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ, ONCOLÓGICA DE VALL HEBRONInventors: Laura Soucek, Marie-Eve Beaulieu
-
Patent number: 10968273Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.Type: GrantFiled: May 14, 2018Date of Patent: April 6, 2021Assignees: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTTTUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
-
Patent number: 10583191Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.Type: GrantFiled: December 18, 2017Date of Patent: March 10, 2020Assignees: MOSAIC BIOMEDICALS SLU, FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL HEBRON, FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATSInventors: Joan Seoane Suarez, Judit Anido Folgueira
-
Patent number: 10370434Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.Type: GrantFiled: May 7, 2014Date of Patent: August 6, 2019Assignee: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRONInventors: Laura Soucek, Marie-Eve Beaulieu
-
Publication number: 20190119373Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.Type: ApplicationFiled: May 14, 2018Publication date: April 25, 2019Applicants: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
-
Patent number: 10206999Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.Type: GrantFiled: January 26, 2018Date of Patent: February 19, 2019Assignees: Mosaic Biomedicals, S.L., Fundació Privada Institut d'Investigació Oncológica de Vall Hebron, Fundació Privada Institució Catalana de Recerca | Estudis AvançatsInventors: Joan Seoane Suarez, Judit Anido Folgueira
-
Publication number: 20160122415Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.Type: ApplicationFiled: May 7, 2014Publication date: May 5, 2016Applicant: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (FPIIOVH)Inventors: Laura SOUCEK, Marie-Eve BEAULIEU
-
Publication number: 20150139989Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.Type: ApplicationFiled: January 5, 2015Publication date: May 21, 2015Applicants: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
-
Patent number: 8926956Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.Type: GrantFiled: April 5, 2011Date of Patent: January 6, 2015Assignees: Fundacio Privada Institut d'Investigacio Oncologica Vall d'Hebron (VHIO), Fundacio Privada Institucio Catalana de Recerca I Estudis Avancats (ICREA)Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
-
Patent number: 8741586Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: December 6, 2010Date of Patent: June 3, 2014Assignees: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
-
Publication number: 20130190367Abstract: Compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, where: R1 is selected from the group consisting of: phenyl, and phenyl mono-, di-, or tri-substituted by a radical independently selected from the group consisting of F, Cl, Br, I, (C1-C6)-alkyl, COO-(C1-C6)-alkyl, and (C1-C6)-alkoxy; and R2 is a radical selected from the same group as R1, further including a phenyl substituted in 4-position by a radical independently selected from the group consisting of —O(CH2)CONH(CH2)3CH3 and OCH2COOC(CH3)3, a biphenyl-4-yl, thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted by a radical selected from F and phenyl; inhibit cell proliferation of tumor cells independently of p53 protein and may also induce apoptosis in several tumor cells independently of p53 protein, being useful for the treatment of several types of cancer.Type: ApplicationFiled: August 29, 2011Publication date: July 25, 2013Applicants: UNIVERSITAT DE BARCELONA, FUNDACIO PRIVADA INSTITUT DE RECERCA BIOMEDICA DE BARCELONA, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE, FUNDACIO PRIVADA PARC CIENTÍFIC DE BARCELONAInventors: Joan Gil Santano, Rodolfo Lavilla Grífols, Fernando Albericio Palomera, Alba Pérez Perarnau, Sara Preciado Gallego, Diana Mª González Gironès, Daniel Iglesias Serret, Rosario Ramón Albalate
-
Patent number: 8389227Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: June 5, 2009Date of Patent: March 5, 2013Assignees: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recera I Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres
-
Publication number: 20090311262Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognises an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: ApplicationFiled: June 5, 2009Publication date: December 17, 2009Applicants: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres